Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
25078274
DOI
10.1177/1352458514541978
PII: 1352458514541978
Knihovny.cz E-zdroje
- Klíčová slova
- Neuromyelitis optica, autologous stem cell transplantation, disease outcome,
- MeSH
- autologní transplantace MeSH
- dospělí MeSH
- hodnocení výsledků zdravotní péče metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- následné studie MeSH
- neuromyelitis optica chirurgie MeSH
- registrace * MeSH
- transplantace hematopoetických kmenových buněk škodlivé účinky metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis. OBJECTIVE: The European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) conducted a retrospective survey to analyze disease outcome following autologous stem cell transplantation (ASCT). METHODS: This retrospective multicenter study assessed the efficacy and safety of ASCT in 16 patients suffering from refractory NMO reported to the EBMT registry between 2001 and 2011. RESULTS: Fifteen patients were successfully mobilized with cyclophosphamide (Cy) and G-CSF, one with G-CSF alone. All patients received an unmanipulated autologous peripheral blood stem cell graft, after conditioning with BEAM plus anti-thymocyte globulin (ATG, n = 9 patients), thiotepa-Cy (n = 3) or Cy (200 mg/kg) plus ATG (n = 4). After a median follow-up of 47 months, three of 16 cases were progression and treatment free, while in the remaining 13 patients further treatments were administered for disability progression or relapse after ASCT. Altogether, relapse-free survival at three and five years was 31% and 10%, respectively, while progression-free survival remained 48% at three and five years. CONCLUSIONS: In these NMO patients, highly resistant to conventional treatment, ASCT allows for temporary control of the disease, despite a tendency to progress or relapse in the long term.
Department of Haematology Careggi University Hospital Italy
Department of Internal Medicine Ribeirão Preto Medical School University of São Paulo Brazil
Department of Neuroscience Ophthalmology and Genetics San Martino Hospital University of Genoa Italy
Department of Neuroscience Uppsala University Sweden
Division of Hematology San Martino Hospital Italy
Division of Hematology University Hospital Sweden
EBMT Study Office Hôpital Saint Antoine France
Hematology and Bone Marrow Transplantation Unit San Raffaele Scientific Institute Italy
Neurology Department Vita Salute San Raffaele University San Raffaele Scientific Institute Italy
Citace poskytuje Crossref.org